Dr. Philipp Hoffmann
Director, Business Development
Daiichi Sankyo/U3 Pharma: development of innovative cancer therapies.
The biotech company U3 Pharma, which belongs to Daiichi Sankyo since 2008, is a source of several new oncology compounds for the Japanese mother company. Most advanced is U3-1287, a anti-HER3 antibody. That could lead to a new cancer drug with high benefits for the patients. With its innovative research and development U3 Pharma contributes to the goal of Daiichi Sankyo to build up a top-ten oncology pipeline till 2015.
[ close ]
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation. Any statements, information and opinions contained in this broadcast,
in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend
projections and any estimated earnings are or may be forward looking statements and as such involve risks and uncertainties. Actual results and developments may differ materially from those expressed
or implied by these statements depending on a variety of factors.
This broadcast is brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any
loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.